UK startup Hyris has successfully completed a Series A round led by Astanor Ventures, alongside participation from Italian investors including NEOS Medica, Idb Holding, the holding company controlling Indena, and Pi Campus, a venture capital firm that invests in AI-applied startups.
Since its founding in 2014, Hyris has built a leading integrated platform for DNA testing. With food scandals on the rise in all parts of the world, and more companies laser-focused on quality assurance and supply chain transparency, Hyris offers high efficacy lab-quality testing that’s convenient and scalable. Hyris also offers an at-scale library of food safety data, to help global industries stay up to date.
In response to the COVID-19 crisis, the startup has also leveraged its products to test for the presence of COVID-19 pathogens using World Health Organization compliant reagents. Together its bCUBE (miniaturized device for the analysis of nucleic acids), bAPP (a web app software that controls multiple bCUBEs), and bKIT (a SARS-CoV-2 Environmental testing kit, developed specifically to test environmental surfaces) work together to test and monitor environments.
The fresh funds raised will allow Hyris to strengthen its commercial deployment and marketing, and make real-time and transparent food safety testing viable, available and scalable for any market player. Hyris will also strengthen its offering for the pharmaceutical, virology and epidemiology sectors.
“With as much as 10% of all foods we consume tainted by adulteration, there could be no better time to disrupt the market and create a healthier, more trusted food system”, explained George Coelho, co-founder and Partner of Astanor Ventures.
Stefano Lo Priore, Hyris’ founder and CEO, commented: “We are excited to join forces with Astanor, a top deep-tech venture capital fund. With the support of Cross Border Growth Capital, we were in the position to choose the best investor among different international VC funds interested in us.”